European cyclicals could be vulnerable

Global manufacturing activity dropped sharply at the start of the Covid-19 outbreak, but then rebounded just as quickly, sparking sharp positive moves in cyclical stocks. Now, valuations for some of these are looking stretched, and any moderation in the growth of new manufacturing orders could make cyclicals vulnerable to a de-rating. Cyclical companies will need to deliver on earnings expectations to support valuations.

In the early days of the Covid-19 crisis, orders by purchasing managers in the manufacturing sectors collapsed as they anticipated weak demand ahead. In response, investors flocked to defensive companies and sold cyclicals - a typical reaction during economic downturns. But it wasn’t long before the pendulum swung the other way: when manufacturing new orders rebounded, signalling higher expected demand, cyclicals outperformed while defensives underperformed.

This week’s Chart Room takes a deeper dive into the relationship between manufacturing data and the outlook for cyclical versus defensive stocks. Looking at three decades of benchmark US PMI data from the Institute of Supply Management we see that an environment of rising ISM new orders has historically tended to mean that commodity and capital goods sectors outperform, while staples and utilities fared worse than the market. This correlation is especially apparent when it comes to historical European equity performance, given the diversified revenue streams of Europe’s larger companies.

 

 

 

The concern now, given the recent sharp rebound in cyclical stocks, is that markets have gotten ahead of themselves. With many leading indicators near peak levels and production rebounding strongly, some cyclical valuations in Europe are reaching heights that have not been seen for at least 45 years, except for a brief period after the Eurozone crisis, when earnings became depressed and dividends were cut.

The market is anticipating approximately 40 per cent growth in earnings in 2021 and applying high multiples to those earnings. These lofty forecasts could set the stage for a correction if companies fail to deliver. Many factors could trigger a valuation reset, such as stimulus measures being tapered or a worse-than-expected second wave of Covid-19 in Europe.
 
If a fast recovery doesn’t play out, the pendulum could swing yet again with the effect that cyclicals could potentially de-rate and defensives outperform in the short term. However, though cyclicals as a group appear to be expensive, there are still examples of individual companies in Europe that are trading at compelling valuations while providing exposure to the recovery. Investors should be selective and tread cautiously.

 

 

 

This document is issued by FIL Responsible Entity (Australia) Limited ABN 33 148 059 009, AFSL No. 409340 (“Fidelity Australia”).  Fidelity Australia is a member of the FIL Limited group of companies commonly known as Fidelity International.

Investments in overseas markets can be affected by currency exchange and this may affect the value of your investment. Investments in small and emerging markets can be more volatile than investments in developed markets.

This document is intended for use by advisers and wholesale investors. Retail investors should not rely on any information in this document without first seeking advice from their financial adviser. This document has been prepared without taking into account your objectives, financial situation or needs. You should consider these matters before acting on the information.  You should also consider the relevant Product Disclosure Statements (“PDS”) for any Fidelity Australia product mentioned in this document before making any decision about whether to acquire the product. The PDS can be obtained by contacting Fidelity Australia on 1800 119 270 or by downloading it from our website at www.fidelity.com.au. This document may include general commentary on market activity, sector trends or other broad-based economic or political conditions that should not be taken as investment advice. Information stated herein about specific securities is subject to change. Any reference to specific securities should not be taken as a recommendation to buy, sell or hold these securities. While the information contained in this document has been prepared with reasonable care, no responsibility or liability is accepted for any errors or omissions or misstatements however caused. This document is intended as general information only. The document may not be reproduced or transmitted without prior written permission of Fidelity Australia. The issuer of Fidelity’s managed investment schemes is FIL Responsible Entity (Australia) Limited ABN 33 148 059 009. Reference to ($) are in Australian dollars unless stated otherwise. 

© 2020 FIL Responsible Entity (Australia) Limited. Fidelity, Fidelity International and the Fidelity International logo and F symbol are trademarks of FIL Limited.

Share:
 
 

Want more insights like this?

Get our free, monthly e-newsletter bringing you valuable insights, opinion and education.

Subscribe